Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Synthon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Zydus Lifesciences in Pact with Synthon for Specialty Oncology Product in US
Details : Zydus to handle NDA submission and commercialisation in the US and Synthon to lead development and manufacturing for oncology product.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Synthon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Omexa Formulary
Deal Size : Undisclosed
Deal Type : Agreement
lpca Laboratories Enters into Technology Transfer Agreement with Omexa Formulary
Details : Under the agreement, Omexa will be responsible for developing an anti-cancer biosimilar drug from the initial stages of development through clinical trials, leading to its eventual commercial launch.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Omexa Formulary
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Natco Pharma
Deal Size : $2.0 million
Deal Type : Financing
NATCO Invests US$ 2 Million in Cellogen Therapeutics
Details : Proceeds will support the development of a chimeric antigen receptor T cell therapy program at Cellogen Therapeutics, genetically engineering T cells to target cancer cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Natco Pharma
Deal Size : $2.0 million
Deal Type : Financing